Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model
- 5 February 2014
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 31 (4) , 477-486
Abstract
Aims: To build a flexible and comprehensive long‐term Type 1 diabetes mellitus model incorporating the most up‐to‐date methodologies to allow a number of cost‐effectiveness evaluations.Methods: This paper describes the conceptual modelling, model implementation and model validation of the Sheffield Type 1 Diabetes Policy Model (version 1.0), developed through funding by the UK National Institute for Health Research as part of the Dose Adjustment for Normal Eating research programme. The model is an individual patient‐level simulation model of Type 1 diabetes and it includes long‐term microvascular (retinopathy, neuropathy and nephropathy) and macrovascular (myocardial infarction, stroke, revascularization and angina) diabetes‐related complications and acute adverse events (severe hypoglycaemia and diabetic ketoacidosis). The occurrence of these diabetes‐related complications in the model is linked to simulated individual patient‐level risk factors, including HbA1c, age, duration of diabetes, lipids and blood pressure. Transition probabilities were modelled based on a combination of existing risk functions, published trials, epidemiological studies and individual‐level data from the Dose Adjustment for Normal Eating research programme.Results: The model takes a lifetime perspective, estimating the impact of interventions on costs, clinical outcomes, survival and quality‐adjusted life years. Validation of the model suggested that, for almost all diabetes‐related complications predicted, event rates were within 10% of the normalized rates reported in the studies used to build the model.Conclusions: The model is highly flexible and has broad potential application to evaluate the Dose Adjustment for Normal Eating research programme, other structured diabetes education programmes and other interventions for Type 1 diabetes.Keywords
This publication has 21 references indexed in Scilit:
- Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UKCurrent Medical Research and Opinion, 2007
- Development and Validation of the Economic Assessment of Glycemic Control and Long-Term Effects of Diabetes (EAGLE) ModelDiabetes Technology & Therapeutics, 2006
- Cost‐effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UKDiabetic Medicine, 2004
- Retinal Vessel Diameters and the Incidence of Gross Proteinuria and Renal Insufficiency in People With Type 1 DiabetesDiabetes, 2004
- The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-makingCurrent Medical Research and Opinion, 2004
- Retinal Vascular Changes and 20-Year Incidence of Lower Extremity Amputations in a Cohort With DiabetesArchives of internal medicine (1960), 2003
- ArchimedesDiabetes Care, 2003
- Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trialBMJ, 2002
- Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemiaDiabetes Care, 1997
- The Effect of Intensive Diabetes Therapy on the Development and Progression of NeuropathyAnnals of Internal Medicine, 1995